adplus-dvertising
Connect with us

Health

How plants can play a role in the future of fighting COVID, RSV and even the common cold

Published

 on

Inside a greenhouse perched atop a University of Ottawa building, there are hundreds of plants that are part of a vaccine revolution offering hope for an end to the pandemic.

A team of scientists at uOttawa, led by virologist Marc-André Langlois in collaboration with biologist Allyson MacLean, is aiming to create something new — a plant-based mucosal vaccine that people could spray into their nostrils to boost their protection against COVID-19.Langlois pictures people picking up the nasal vaccine from a drug store and taking it home to top-up their COVID-19 defences to prevent infection.

The Nicotiana benthamiana plants growing in the university greenhouse — weeds in their native Australia — work as a vaccine bio-factory to produce viral proteins that act as antigens to create an immune response against COVID-19.

The nasal vaccine would act as a booster for those who have already received an mRNA COVID vaccine or have been infected, said Langlois, a professor in the faculty of medicine at the university and executive director of the Coronavirus Variants Rapid Response Network.

300x250x1
“We are aiming to capitalize on the fact that most people will have received prior vaccines or had an infection and acquired immunity.”Work on the prototype nasal spray vaccine is still in the early stages, but preliminary results have successfully boosted antibody protection in mice previously given mRNA COVID-19 vaccines. The next step is to challenge mice with the virus to see if the vaccine confers protection.

Eventually, studies in humans are needed to further develop a potential plant-based mucosal vaccine, which would require additional funding, said Langlois.

Marc-André Langlois and Allyson MacLean, uOttawa researchers, are working on a nasal COVID booster vaccine that is plant based.
Marc-André Langlois and Allyson MacLean, uOttawa researchers, are working on a nasal COVID booster vaccine that is plant based. Photo by Jean Levac /Postmedia

Scientists at McMaster University in Hamilton are further along in developing a mucosal vaccine for COVID-19.

The McMaster mucosal vaccine has demonstrated broad, long-lasting protection against the original strain of SARS-CoV-2 as well as variants of concern. It is currently being tested in healthy adults who already received two doses of a COVID mRNA vaccine.

Why, at this point in the pandemic, with highly successful mRNA and other vaccines widely available, are Canadian researchers working to develop new mucosal vaccines against COVID-19? And why should people care?Because mucosal vaccines hold the hope of ending the pandemic, according to uOttawa epidemiologist Raywat Deonandan.

Mucosal vaccines — which work by blocking infection where the virus enters the body in areas such as the mouth and nose — have the potential to prevent infections and transmission of COVID-19. That is something existing intramuscular vaccines, which produce neutralizing antibodies that circulate throughout the body, cannot do very well. Mucosal vaccines are typically sprayed in the nostrils or the mouth while traditional vaccines are injected.

“We don’t want to be mildly sick. We don’t want to be sick at all,” says Langlois.“These (mucosal) vaccines are focused on completely blocking infection.” That goes for COVID-19 as well as all respiratory virus infections, including RSV and the common cold, he said.

Current COVID-19 vaccines administered via needles, produced within months of pandemic declarations, were approved for emergency use based on proof that they could prevent severe disease and deaths, which they did. They did not entirely stop infection or transmission.

With COVID-19 transmission continuing at high levels, Deonandan said the possibilities of mucosal vaccines are exciting.

Dr. Raywat Deonandan is an epidemiologist, author, journalist and global health specialist.
Dr. Raywat Deonandan is an epidemiologist, author, journalist and global health specialist. Photo by ERROL MCGIHON /Postmedia

In the best-case scenario, they could end the pandemic, he said. “I think in the end it depends on what they end up looking like. But that is the hope.”

Not only do they have the potential to stop transmission, preventing further infections and mutations, but they are also potentially longer lasting than current intramuscular vaccines, whose immunity can wane within months.Because mucosal vaccines can be delivered through the mouth and nose, they can be self-administered, making delivery significantly easier and cheaper, something that is crucial in parts of the world with fewer resources. They also do away with the need for injections.

Deonandan sees them as the next generation of COVID-19 vaccines, but notes there has been a lack of enthusiasm by governments and drug companies about underwriting the financial risk, as they did with the first-generation of vaccines.

Other countries, including India, are using mucosal COVID-19 vaccines. But none have been approved in Canada.The mucosal vaccine research at uOttawa is to develop a prototype, Langlois said. Where it goes from there depends on funding. “Right now it is limited, until we make a strong case that it is effective and then we can increase our team size to move things along faster.

“There are still very large gaps in knowledge in what makes a good antigen for a mucosal vaccines,” said Langlois. “We are decades behind the standard intramuscular vaccines in terms of our understanding of what makes a good mucosal vaccine.

Mucosal vaccines in general are relatively new and research to make effective vaccines is ongoing, said Langlois. It is important work toward making Canada more self-sufficient when it comes to vaccine development and production, he said.

“Canada needs much higher sovereignty over vaccine production and bio-manufacturing of drugs. We are highly reliant on foreign industry. That has been a lesson of the pandemic.”
OTTAWA – March 02, 2023 – Marc-André Langlois and Allyson MacLean, uOttawa researchers, are working on a nasal covid booster vaccine that is plant based. Assignment 138797 Photo by Jean Levac/Ottawa Citizen
OTTAWA – March 02, 2023 – Marc-André Langlois and Allyson MacLean, uOttawa researchers, are working on a nasal covid booster vaccine that is plant based. Assignment 138797 Photo by Jean Levac/Ottawa Citizen Photo by Jean Levac /Postmedia

The goal of Canada becoming less reliant on foreign industry was delivered a blow last month when Medicago, a plant-based COVID-19 vaccine manufacturer, shut down its operations in Quebec after its sole shareholder decided to no longer invest in the company. Medicago’s COVID-19 vaccines had been approved by Health Canada but the World Health Organization initially rejected the vaccine because of its ties to tobacco company Phillip Morris.

MacLean, an assistant professor in the department of biology at the university and the biologist collaborating with Langlois, called it a big loss for Canada in the burgeoning field of biopharming — the use of plants to produce pharmaceuticals.

It is more reason for Canada to continue investing in research, she said.The work at uOttawa is pushing the boundaries of vaccine research.

“Not only are we trying to develop a mucosal vaccine, we are trying to do it in plants,” said MacLean.

There is still work to be done to get plants to produce similar amounts of viral proteins as eggs or animal cells, which are used more commonly in vaccine production, MacLean said. But the advantages of using plants are numerous. Among them, plant-based vaccines are inexpensive and quick to produce and contamination is less likely than with vaccines produced in eggs and animal cells.

“Plants are dead cheap to work with; you need soil, you need a bit of fertilizer, you need sun and water, and that’s it,” said MacLean.

Marc-André Langlois and Allyson MacLean.
Marc-André Langlois and Allyson MacLean. Photo by Jean Levac /Postmedia
728x90x4

Source link

Continue Reading

Health

Cancer Awareness Month – Métis Nation of Alberta

Published

 on



All Posts

Cancer Awareness Month

Posted on: Apr 18, 2024

April is Cancer Awareness Month

As we recognize Cancer Awareness Month, we stand together to raise awareness, support those affected, advocate for prevention, early detection, and continued research towards a cure. Cancer is the leading cause of death for Métis women and the second leading cause of death for Métis men. The Otipemisiwak Métis Government of the Métis Nation Within Alberta is working hard to ensure that available supports for Métis Citizens battling cancer are culturally appropriate, comprehensive, and accessible by Métis Albertans at all stages of their cancer journey.

300x250x1

Receiving a cancer diagnosis, whether for yourself or a loved one, can feel overwhelming, leaving you unsure of where to turn for support. In June, our government will be launching the Cancer Supports and Navigation Program which will further support Métis Albertans and their families experiencing cancer by connecting them to OMG-specific cancer resources, external resources, and providing navigation support through the health care system. This program will also include Métis-specific peer support groups for those affected by cancer.

With funding from the Canadian Partnership Against Cancer (CPAC) we have also developed the Métis Cancer Care Course to ensure that Métis Albertans have access to culturally safe and appropriate cancer services. This course is available to cancer care professionals across the country and provides an overview of who Métis people are, our culture, our approaches to health and wellbeing, our experiences with cancer care, and our cancer journey.

Together, we can make a difference in the fight against cancer and ensure equitable access to culturally safe and appropriate care for all Métis Albertans. Please click on the links below to learn more about the supports available for Métis Albertans, including our Compassionate Care: Cancer Transportation program.

I wish you all good health and happiness!

Bobbi Paul-Alook
Secretary of Health & Seniors

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options – The Conversation

Published

 on


You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes? In Canada, diabetes affects approximately 10 per cent of the general population. Of those cases, 90 per cent have Type 2 diabetes.

This metabolic disorder is characterized by persistent high blood sugar levels, which can be accompanied by secondary health challenges, including a higher risk of stroke and kidney disease.

Locks and keys

In Type 2 diabetes, the body struggles to maintain blood sugar levels in an acceptable range. Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells. This equilibrium needs to be tightly controlled and is regulated by a lock and key system.

300x250x1

In the body’s attempt to manage blood sugar levels and ensure that cells receive the right amount of energy, the pancreatic hormone, insulin, functions like a key. Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.

Unfortunately, this lock and key system doesn’t always perform as expected. The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.

All forms of diabetes share the challenge of high blood sugar levels; however, diabetes is not a singular condition; it exists as a spectrum. Although diabetes is broadly categorized into two main types, Type 1 and Type 2, each presents a diversity of subtypes, especially Type 2 diabetes.

These subtypes carry their own characteristics and risks, and do not respond uniformly to the same treatments.

To better serve people living with Type 2 diabetes, and to move away from a “one size fits all” approach, it is beneficial to understand which subtype of Type 2 diabetes a person lives with. When someone needs a blood transfusion, the medical team needs to know the patient’s blood type. It should be the same for diabetes so a tailored and effective game plan can be implemented.

This article explores four unique subtypes of Type 2 diabetes, shedding light on their causes, complications and some of their specific treatment avenues.

Severe insulin-deficient diabetes: We’re missing keys!

In severe insulin-deficient diabetes, beta cells limit production of the keys that unlock cells to allow entry of sugar from the blood.
(Lili Grieco-St-Pierre, Jennifer Bruin/Created with BioRender.com)

Insulin is produced by beta cells, which are found in the pancreas. In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike. Ultimately, there are fewer keys in the body to unlock the cells and allow entry of sugar from the blood.

SIDD primarily affects younger, leaner individuals, and unfortunately, increases the risk of eye disease and blindness, among other complications. Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.

Severe insulin-resistant diabetes: But it’s always locked!

A diagram of three closed locks and lots of keys

In severe insulin-resistant diabetes, the locks start ignoring the keys, triggering the beta cells to produce even more keys to compensate.
(Lili Grieco-St-Pierre, Jennifer Bruin/Created with BioRender.com)

In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys. As a result, the beta cells produce even more keys to compensate. This can be measured as high levels of insulin in the blood, also known as hyperinsulinemia.

This resistance to insulin is particularly prominent in individuals with higher body weight. Patients with SIRD have an increased risk of complications such as fatty liver disease. There are many treatment avenues for these patients but no consensus about the optimal approach; patients often require high doses of insulin.

Mild obesity-related diabetes: The locks are sticky!

Illustration of a lock and key

In mild obesity-related diabetes, the locks are ‘sticky,’ making it difficult for the keys to open the locks.
(Lili Grieco-St-Pierre, Jennifer Bruin/Created with BioRender.com)

Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight. Unlike more severe subtypes, MOD is characterized by a more measured response to insulin. The locks are “sticky,” so it is challenging for the key to click in place and open the lock. While MOD is connected to body weight, the comparatively less severe nature of MOD distinguishes it from other diabetes subtypes.

To minimize complications, treatment should include maintaining a healthy diet, managing body weight, and incorporating as much aerobic exercise as possible. This is where drugs like Ozempic can be prescribed to control the evolution of the disease, in part by managing body weight.

Mild age-related diabetes: I’m tired of controlling blood sugar!

Illustration of a lock and a beta cell

In people with mild age-related diabetes, both the locks and the beta cells that produce keys are tired, resulting in fewer keys and stubborn locks.
(Lili Grieco-St-Pierre, Jennifer Bruin/Created with BioRender.com)

Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications.

Among the different subtypes of diabetes, MARD is the most common.

Unique locks, varied keys

While efforts have been made to classify diabetes subtypes, new subtypes are still being identified, making proper clinical assessment and treatment plans challenging.

In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s. Despite initial skepticism from the scientific community, which typically associated Type 2 diabetes with adults rather than children, clinical teams persisted in identifying this as a distinct subtype of Type 2 diabetes, called childhood-onset Type 2 diabetes.




Read more:
Indigenous community research partnerships can help address health inequities


Childhood-onset Type 2 diabetes is on the rise across Canada, but disproportionately affects Indigenous youth. It is undoubtedly linked to the intergenerational trauma associated with colonization in these communities. While many factors are likely involved, recent studies have discovered that exposure of a fetus to Type 2 diabetes during pregnancy increases the risk that the baby will develop diabetes later in life.

Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples. It is hoped that partnered research between communities and researchers will continue to help us understand childhood-onset Type 2 diabetes and how to effectively prevent and treat it.

A mosaic of conditions

Illustration of different subtypes of Type 2 diabetes

Type 2 diabetes is a mosaic of conditions, each with its own characteristics.
(Lili Grieco-St-Pierre, Jennifer Bruin/Created with BioRender.com)

Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics. Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve. However, understanding these subtypes is a good starting point to help doctors create personalized plans for people living with the condition.

While Indigenous communities, lower-income households and individuals living with obesity already face a higher risk of developing Type 2 diabetes than the general population, tailored solutions may offer hope for better management. This emphasizes the urgent need for more precise assessments of diabetes subtypes to help customize therapeutic strategies and management strategies. This will improve care for all patients, including those from vulnerable and understudied populations.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Quebec successfully pushes back against rise in measles cases – CBC.ca

Published

 on


Quebec appears to be winning its battle against the rising tide of measles after 45 cases were confirmed province-wide this year.

“We’ve had no locally transmitted measles cases since March 25, so that’s good news,” said Dr. Paul Le Guerrier, responsible for immunization for Montreal Public Health.

There are 17 patients with measles in Quebec currently, and the most recent case is somebody who was infected while abroad, he said.

300x250x1

But it was no small task to get to this point. 

Le Guerrier said once local transmission was detected, news was spread fast among health centres to ensure proper protocols were followed — such as not letting potentially infected people sit in waiting rooms for hours on end.

Then about 90 staffers were put to work, tracking down those who were in contact with positive cases and are not properly vaccinated. They were given post-exposure prophylaxis, which prevents disease, said Le Guerrier.

From there, a vaccination campaign was launched, especially in daycares, schools and neighbourhoods with low inoculation rates. There was an effort to convince parents to get their children vaccinated.

Vaccination in schools boosted

Some schools, mostly in Montreal, had vaccination rates as low as 30 or 40 per cent.

“Vaccination was well accepted and parents responded well,” said Le Guerrier. “Some schools went from very low to as high as 85 to 90 per cent vaccination coverage.”

But it’s not only children who aren’t properly vaccinated. Le Guerrier said people need two doses after age one to be fully inoculated, and he encouraged people to check their status.

There are all kinds of reasons why people aren’t vaccinated, but it’s only about five per cent who are against immunization, he said. So far, some 10,000 people have been vaccinated against measles province-wide during this campaign, Le Guerrier said. 

The next step is to continue pushing for further vaccination, but he said, small outbreaks are likely in the future as measles is spreading abroad and travellers are likely to bring it back with them.

Need to improve vaccination rate, expert says

Dr. Donald Vinh, an infectious diseases specialist from the McGill University Health Centre, said it’s not time to rest on our laurels, but this is a good indication that public health is able to take action quickly and that people are willing to listen to health recommendations.

“We are not seeing new cases or at least the new cases are not exceeding the number of cases that we can handle,” said Vinh.

“So these are all reassuring signs, but I don’t think it’s a sign that we need to become complacent.”

Vinh said there are also signs that the public is lagging in vaccine coverage and it’s important to respond to this with improved education and access. Otherwise, microbes capitalize on our weaknesses, he said. 

Getting vaccination coverage up to an adequate level is necessary, Vinh said, or more small outbreaks like this will continue to happen.

“And it’s very possible that we may not be able to get one under control if we don’t react quickly enough,” he said.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending